aspirin has been researched along with Carcinoma, Intraepithelial in 6 studies
Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.
acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate the recurrence-free survival (RFS) rate of patients taking cardioprotective aspirin after intravesical bacille Calmette-Guérin (BCG) for high-grade noninvasive urothelial carcinoma of the bladder, as preventing the recurrence of superficial bladder cancer might decrease patient morbidity and mortality from this disease, and nonsteroidal anti-inflammatory agents (NSAIDs) have shown promise in preclinical prevention through inhibition of the prostaglandin pathway and other mechanisms." | 7.75 | Reduced bladder cancer recurrence rate with cardioprotective aspirin after intravesical bacille Calmette-Guérin. ( Bruskewitz, RC; Gee, JR; Hedican, SP; Jarrard, DF; Leverson, GE; Messing, EM; Moon, TD; Nakada, SY, 2009) |
| "To evaluate the recurrence-free survival (RFS) rate of patients taking cardioprotective aspirin after intravesical bacille Calmette-Guérin (BCG) for high-grade noninvasive urothelial carcinoma of the bladder, as preventing the recurrence of superficial bladder cancer might decrease patient morbidity and mortality from this disease, and nonsteroidal anti-inflammatory agents (NSAIDs) have shown promise in preclinical prevention through inhibition of the prostaglandin pathway and other mechanisms." | 3.75 | Reduced bladder cancer recurrence rate with cardioprotective aspirin after intravesical bacille Calmette-Guérin. ( Bruskewitz, RC; Gee, JR; Hedican, SP; Jarrard, DF; Leverson, GE; Messing, EM; Moon, TD; Nakada, SY, 2009) |
| "Furthermore, development of invasive pancreatic cancer in LsL-Kras(G12D); LsL-Trp53(R172H); Pdx1-Cre transgenic mice was partially inhibited by enalapril and aspirin." | 1.36 | The angiotensin-I-converting enzyme inhibitor enalapril and aspirin delay progression of pancreatic intraepithelial neoplasia and cancer formation in a genetically engineered mouse model of pancreatic cancer. ( Bartsch, DK; Buchholz, M; Chen, NM; Feldmann, G; Fendrich, V; Maitra, A; Neef, M; Slater, EP; Waldmann, J, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (50.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gee, JR | 1 |
| Jarrard, DF | 1 |
| Bruskewitz, RC | 1 |
| Moon, TD | 1 |
| Hedican, SP | 1 |
| Leverson, GE | 1 |
| Nakada, SY | 1 |
| Messing, EM | 1 |
| Fendrich, V | 1 |
| Chen, NM | 1 |
| Neef, M | 1 |
| Waldmann, J | 1 |
| Buchholz, M | 1 |
| Feldmann, G | 1 |
| Slater, EP | 1 |
| Maitra, A | 1 |
| Bartsch, DK | 1 |
| Rao, CV | 1 |
| Mohammed, A | 1 |
| Janakiram, NB | 1 |
| Li, Q | 1 |
| Ritchie, RL | 1 |
| Lightfoot, S | 1 |
| Vibhudutta, A | 1 |
| Steele, VE | 1 |
| P'ng, KB | 1 |
| Walsh, MD | 1 |
| Seymour, GJ | 1 |
| Lavin, MF | 1 |
| Gardiner, RA | 1 |
| Witjes, JA | 1 |
| vd Meijden, AP | 1 |
| Doesburg, W | 1 |
| Debruyne, FM | 1 |
| Nightingale, SL | 1 |
1 trial available for aspirin and Carcinoma, Intraepithelial
| Article | Year |
|---|---|
From the Food and Drug Administration.
Topics: Acquired Immunodeficiency Syndrome; Aspirin; BCG Vaccine; Carcinoma in Situ; Clinical Trials as Topi | 1990 |
5 other studies available for aspirin and Carcinoma, Intraepithelial
| Article | Year |
|---|---|
Reduced bladder cancer recurrence rate with cardioprotective aspirin after intravesical bacille Calmette-Guérin.
Topics: Administration, Intravesical; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; | 2009 |
The angiotensin-I-converting enzyme inhibitor enalapril and aspirin delay progression of pancreatic intraepithelial neoplasia and cancer formation in a genetically engineered mouse model of pancreatic cancer.
Topics: Amylases; Angiotensin-Converting Enzyme Inhibitors; Animals; Anticarcinogenic Agents; Aspirin; Carci | 2010 |
Inhibition of pancreatic intraepithelial neoplasia progression to carcinoma by nitric oxide-releasing aspirin in p48(Cre/+)-LSL-Kras(G12D/+) mice.
Topics: Animals; Anticarcinogenic Agents; Aspirin; beta Catenin; Body Weight; Carcinoma in Situ; Carcinoma, | 2012 |
The adverse effect of fibrin-clot inhibiting drugs on intravesical bacillus Calmette-Guérin efficacy for superficial bladder cancer.
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroida | 1993 |
Influence of fibrin clot inhibitors on the efficacy of intravesical Bacillus Calmette-Guérin in the treatment of superficial bladder cancer. The Dutch Southeast Cooperative Urological Group.
Topics: Administration, Intravesical; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; BCG | 1993 |